Health Canada Approves Catena® for Treatment of Friedreich’s Ataxia
News Release Liestal, Switzerland, July 24, 2008 – Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today that Health Canada has approved with conditions SNT-MC17/idebenone for the treatment of Friedreich’s Ataxia. Health Canada’s decision is the first marketing authorization worldwide for any Friedreich’s Ataxia therapy....

